quinta-feira, 5 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

The Download: Anthropic’s IPO, smarter power grids, and exercise pills

View original at technologyreview.com
MIT Technology Review - Ai Research Title: The Download: Anthropic’s IPO, smarter power grids, and exercise pills Date: 2026-10-27 12:10 Source: https://www.technologyreview.com/2026/10/27/1147693/the-download-anthropic-ipo-smarter-power-grids-exercise-pills/ <p class="wp-block-paragraph"><em>This is today’s edition of…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Solar is quietly overtaking nuclear as a global power source, driven by cheap panels and batteries.

    60% confidence
  • Anthropic's public messaging is a master class in narrative capture, presenting it as an AI safety organization, a profit-driven megacorp, and a group creating superhuman technology.

    60% confidence
  • Voluntary safety pledges recently made by AI executives are toothless and unenforceable.

    60% confidence
  • Grok said its AI-generated version of the Odyssey is not historically accurate.

    60% confidence
  • The plastics industry knew decades ago that microplastics could enter the body, with company documents showing concerns from 1974.

    60% confidence

Data points we hold from this source

Anthropic · ipo prospectus length335 pages
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,549 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
The Download: Anthropic’s IPO, smarter power grids, and exercise pills — Source | Via News | pt.VIA.NEWS